This is particularly relevant in patients with obesity, type 2 diabetes, or metabolic syndrome, where dysregulated leptin pathways and impaired β3 signaling may influence clinical outcomes. Here, LEP is linked to obesity due to melanocortin 4 receptor deficiency.